SYSMED-NB

Publikationen

2019

Foo, J. C., Streit, F., Frank, J., Witt, S. H., Treutlein, J., Major Depressive Disorder Working Group of the Psychiatric Genomics, C., Baune, B. T., Moebus, S., Jöckel, K.-H., Forstner, A. J., Nöthen, M. M., Rietschel, M., Sartorius, A.Kranaster, L., 2019. Evidence for increased genetic risk load for major depression in patients assigned to electroconvulsive therapy. Am. J. Med. Genet. B Neuropsychiatr. Genet., 180(1), 35-45. doi.org/10.1002/ajmg.b.32700

Jachimowicz, R. D., Beleggia, F., Isensee, J., Velpula, B. B., Goergens, J., Bustos, M. A., Doll, M. A., Shenoy, A., Checa-Rodriguez, C., Wiederstein, J. L., Baranes-Bachar, K., Bartenhagen, C., Hertwig, F., Teper, N., Nishi, T., Schmitt, A., Distelmaier, F., Lüdecke, H.-J., Albrecht, B., Krüger, M., Schumacher, B., Geiger, T., Hoon, D. S. B., Huertas, P., Fischer, M., Hucho, T., Peifer, M., Ziv, Y., Reinhardt, H. C., Wieczorek, D.Shiloh, Y., 2019. UBQLN4 Represses Homologous Recombination and Is Overexpressed in Aggressive Tumors. Cell. doi.org/10.1016/j.cell.2018.11.024

Korber, V., Yang, J., Barah, P., Wu, Y., Stichel, D., Gu, Z., Fletcher, M. N. C., Jones, D., Hentschel, B., Lamszus, K., Tonn, J. C., Schackert, G., Sabel, M., Felsberg, J., Zacher, A., Kaulich, K., Hubschmann, D., Herold-Mende, C., von Deimling, A., Weller, M., Radlwimmer, B., Schlesner, M., Reifenberger, G., Hofer, T.Lichter, P., 2019. Evolutionary Trajectories of IDH(WT) Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis. Cancer Cell. doi.org/10.1016/j.ccell.2019.02.007

 

2018

Ackermann, S., Cartolano, M., Hero, B., Welte, A., Kahlert, Y., Roderwieser, A., Bartenhagen, C., Walter, E., Gecht, J., Kerschke, L., Volland, R., Menon, R., Heuckmann, J. M., Gartlgruber, M., Hartlieb, S., Henrich, K.-O., Okonechnikov, K., Altmüller, J., Nürnberg, P., Lefever, S., Wilde, B. d., Sand, F., Ikram, F., Rosswog, C., Fischer, J., Theissen, J., Hertwig, F., Singhi, A. D., Simon, T., Vogel, W., Perner, S., Krug, B., Schmidt, M., Rahmann, S., Achter, V., Lang, U., Vokuhl, C., Ortmann, M., Büttner, R., Eggert, A., Speleman, F., O’Sullivan, R. J., Thomas, R. K., Berthold, F., Vandesompele, J., Schramm, A., Westermann, F., Schulte, J. H., Peifer, M.Fischer, M., 2018. A mechanistic classification of clinical phenotypes in neuroblastoma. Science, 362(6419), 1165-1170. doi.org/10.1126/science.aat6768

Correia, M. P., Stojanovic, A., Bauer, K., Juraeva, D., Tykocinski, L.-O., Lorenz, H.-M., Brors, B.Cerwenka, A., 2018. Distinct human circulating NKp30+FcεRIγ+CD8+ T cell population exhibiting high natural killer-like antitumor potential. Proc. Natl. Acad. Sci. U.S.A., 115(26), E5980-E5989. doi.org/10.1073/pnas.1720564115

De Wilde, B., Beckers, A., Lindner, S., Kristina, A., De Preter, K., Depuydt, P., Mestdagh, P., Sante, T., Lefever, S., Hertwig, F., Peng, Z., Shi, L. M., Lee, S., Vandermarliere, E., Martens, L., Menten, B., Schramm, A., Fischer, M., Schulte, J., Vandesompele, J.Speleman, F., 2018. The mutational landscape of MYCN, Lin28b and ALK(F1174L) driven murine neuroblastoma mimics human disease. Oncotarget, 9(9), 8334-8349. doi.org/10.18632/oncotarget.23614

Depuydt, P., Boeva, V., Hocking, T. D., Cannoodt, R., Ambros, I. M., Ambros, P. F., Asgharzadeh, S., Attiyeh, E. F., Combaret, V., Defferrari, R., Fischer, M., Hero, B., Hogarty, M. D., Irwin, M. S., Koster, J., Kreissman, S., Ladenstein, R., Lapouble, E., Laureys, G., London, W. B., Mazzocco, K., Nakagawara, A., Noguera, R., Ohira, M., Park, J. R., Potschger, U., Theissen, J., Tonini, G. P., Valteau-Couanet, D., Varesio, L., Versteeg, R., Speleman, F., Maris, J. M., Schleiermacher, G.De Preter, K., 2018. Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients. J Natl Cancer Inst, 110(10), 1084-1093. doi.org/10.1093/jnci/djy022

Meder, L., König, K., Dietlein, F., Macheleidt, I., Florin, A., Ercanoglu, M. S., Rommerscheidt-Fuss, U., Koker, M., Schön, G., Odenthal, M., Klein, F., Büttner, R., Schulte, J. H., Heukamp, L. C.Ullrich, R. T., 2018. LIN28B enhanced tumorigenesis in an autochthonous KRASG12V-driven lung carcinoma mouse model. Oncogene, 37(20), 2746-2756. doi.org/10.1038/s41388-018-0158-7

2017

Benary, U., Wolf, E.Wolf, J., 2017. Mathematical modelling of promoter occupancies in MYC-dependent gene regulation. Genomics and Computational Biology, 3(2), 54. doi.org/10.18547/gcb.2017.vol3.iss2.e54

Henssen, A. G., Odersky, A., Szymansky, A., Seiler, M., Althoff, K., Beckers, A., Speleman, F., Schäfers, S., De Preter, K., Astrahanseff, K., Struck, J., Schramm, A., Eggert, A., Bergmann, A.Schulte, J. H., 2017. Targeting tachykinin receptors in neuroblastoma. Oncotarget, 8(1), 430-443. doi.org/10.18632/oncotarget.13440

Rosswog, C., Schmidt, R., Oberthuer, A., Juraeva, D., Brors, B., Engesser, A., Kahlert, Y., Volland, R., Bartenhagen, C., Simon, T., Berthold, F., Hero, B., Faldum, A.Fischer, M., 2017. Molecular Classification Substitutes for the Prognostic Variables Stage, Age, and MYCN Status in Neuroblastoma Risk Assessment. Neoplasia, 19(12), 982-990. doi.org/10.1016/j.neo.2017.09.006

Ryl, T., Kuchen, E. E., Bell, E., Shao, C., Flórez, A. F., Mönke, G., Gogolin, S., Friedrich, M., Lamprecht, F., Westermann, F.Höfer, T., 2017. Cell-Cycle Position of Single MYC-Driven Cancer Cells Dictates Their Susceptibility to a Chemotherapeutic Drug. Cell Syst, 5(3), 237-250.e8. doi.org/10.1016/j.cels.2017.07.005

Shao, C.Hofer, T., 2017. Robust classification of single-cell transcriptome data by nonnegative matrix factorization. Bioinformatics, 33(2), 235-242. doi.org/10.1093/bioinformatics/btw607

Thole, T. M., Lodrini, M., Fabian, J., Wuenschel, J., Pfeil, S., Hielscher, T., Kopp-Schneider, A., Heinicke, U., Fulda, S., Witt, O., Eggert, A., Fischer, M.Deubzer, H. E., 2017. Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival. Cell Death Dis, 8(3), e2635. doi.org/10.1038/cddis.2017.49

2016

Althoff, K., Schulte, J. H.Schramm, A., 2016. Towards diagnostic application of non-coding RNAs in neuroblastoma. Expert Rev. Mol. Diagn., 16(12), 1307-1313. doi.org/10.1080/14737159.2016.1256207

Eccles, R. L., Czajkowski, M. T., Barth, C., Müller, P. M., McShane, E., Grunwald, S., Beaudette, P., Mecklenburg, N., Volkmer, R., Zühlke, K., Dittmar, G., Selbach, M., Hammes, A., Daumke, O., Klussmann, E., Urbé, S.Rocks, O., 2016. Bimodal antagonism of PKA signalling by ARHGAP36. Nat Commun, 7, 12963. doi.org/10.1038/ncomms12963

Fabian, J., Opitz, D., Althoff, K., Lodrini, M., Hero, B., Volland, R., Beckers, A., de Preter, K., Decock, A., Patil, N., Abba, M., Kopp-Schneider, A., Astrahantseff, K., Wunschel, J., Pfeil, S., Ercu, M., Kunkele, A., Hu, J., Thole, T., Schweizer, L., Mechtersheimer, G., Carter, D., Cheung, B. B., Popanda, O., von Deimling, A., Koster, J., Versteeg, R., Schwab, M., Marshall, G. M., Speleman, F., Erb, U., Zoeller, M., Allgayer, H., Simon, T., Fischer, M., Kulozik, A. E., Eggert, A., Witt, O., Schulte, J. H.Deubzer, H. E., 2016. MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma. Oncotarget, 7(41), 66344-66359. doi.org/10.18632/oncotarget.11662

Formicola, D., Petrosino, G., Lasorsa, V. A., Pignataro, P., Cimmino, F., Vetrella, S., Longo, L., Tonini, G. P., Oberthuer, A., Iolascon, A., Fischer, M.Capasso, M., 2016. An 18 gene expression-based score classifier predicts the clinical outcome in stage 4 neuroblastoma. J Transl Med, 14(1), 142. doi.org/10.1186/s12967-016-0896-7

Henrich, K. O., Bender, S., Saadati, M., Dreidax, D., Gartlgruber, M., Shao, C., Herrmann, C., Wiesenfarth, M., Parzonka, M., Wehrmann, L., Fischer, M., Duffy, D. J., Bell, E., Torkov, A., Schmezer, P., Plass, C., Hofer, T., Benner, A., Pfister, S. M.Westermann, F., 2016. Integrative Genome-Scale Analysis Identifies Epigenetic Mechanisms of Transcriptional Deregulation in Unfavorable Neuroblastomas. Cancer Res, 76(18), 5523-37. doi.org/10.1158/0008-5472.CAN-15-2507

Henssen, A., Althoff, K., Odersky, A., Beckers, A., Koche, R., Speleman, F., Schäfers, S., Bell, E., Nortmeyer, M., Westermann, F., De Preter, K., Florin, A., Heukamp, L., Spruessel, A., Astrahanseff, K., Lindner, S., Sadowski, N., Schramm, A., Astorgues-Xerri, L., Riveiro, M. E., Eggert, A., Cvitkovic, E.Schulte, J. H., 2016. Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition. Clin. Cancer Res., 22(10), 2470-2481. doi.org/10.1158/1078-0432.CCR-15-1449

Ikram, F., Ackermann, S., Kahlert, Y., Volland, R., Roels, F., Engesser, A., Hertwig, F., Kocak, H., Hero, B., Dreidax, D., Henrich, K.-O., Berthold, F., Nürnberg, P., Westermann, F.Fischer, M., 2016. Transcription factor activating protein 2 beta (TFAP2B) mediates noradrenergic neuronal differentiation in neuroblastoma. Mol Oncol, 10(2), 344-359. doi.org/10.1016/j.molonc.2015.10.020

Lodrini, M., Poschmann, G., Schmidt, V., Wünschel, J., Dreidax, D., Witt, O., Höfer, T., Meyer, H. E., Stühler, K., Eggert, A.Deubzer, H. E., 2016. Minichromosome Maintenance Complex Is a Critical Node in the miR-183 Signaling Network of MYCN-Amplified Neuroblastoma Cells. J. Proteome Res., 15(7), 2178-2186. doi.org/10.1021/acs.jproteome.6b00134

Lorenzin, F., Benary, U., Baluapuri, A., Walz, S., Jung, L. A., Eyss, B. v., Kisker, C., Wolf, J., Eilers, M.Wolf, E., 2016. Different promoter affinities account for specificity in MYC-dependent gene regulation. Elife, 5, e15161. doi.org/10.7554/eLife.15161

Ribeiro, D., Klarqvist, M. D. R., Westermark, U. K., Oliynyk, G., Dzieran, J., Kock, A., Savatier Banares, C., Hertwig, F., Johnsen, J. I., Fischer, M., Kogner, P., Lovén, J.Arsenian Henriksson, M., 2016. Regulation of Nuclear Hormone Receptors by MYCN-Driven miRNAs Impacts Neural Differentiation and Survival in Neuroblastoma Patients. Cell Rep, 16(4), 979-993. doi.org/10.1016/j.celrep.2016.06.052

Thompson, D., Vo, K. T., London, W. B., Fischer, M., Ambros, P. F., Nakagawara, A., Brodeur, G. M., Matthay, K. K.DuBois, S. G., 2016. Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project. Cancer, 122(6), 935-945. doi.org/10.1002/cncr.29848

 

2015

Carter, D.R., Murray, J., Cheung, B.B., Gamble, L., Koach, J., Tsang, J., Sutton, S., Kalla, H., Syed, S., Gifford, A.J., Issaeva, N., Biktasova, A., Atmadibrata, B., Sun, Y., Sokolowski, N., Ling, D., Kim, P.Y., Webber, H., Clark, A., Ruhle, M., Liu, B., Oberthuer, A., Fischer, M., Byrne, J., Saletta, F., Thwe, L.M., Purmal, A., Haderski, G., Burkhart, C., Speleman, F., De Preter, K., Beckers, A., Ziegler, D.S., Liu, T., Gurova, K.V., Gudkov, A.V., Norris, M.D., Haber, M., Marshall, G.M., 2015. Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma. Sci Transl Med 7, 312ra176. doi.org/10.1126/scitranslmed.aab1803

Fey, D., Halasz, M., Dreidax, D., Kennedy, S.P., Hastings, J.F., Rauch, N., Munoz, A.G., Pilkington, R., Fischer, M., Westermann, F., Kolch, W., Kholodenko, B.N., Croucher, D.R., 2015. Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patients. Sci Signal 8, ra130. doi.org/10.1126/scisignal.aab0990

Lindner, S., Bachmann, H.S., Odersky, A., Schaefers, S., Klein-Hitpass, L., Hero, B., Fischer, M., Eggert, A., Schramm, A., Schulte, J.H., 2015. Absence of telomerase reverse transcriptase promoter mutations in neuroblastoma. Biomed Rep 3, 443–446. doi.org/10.3892/br.2015.463

Peifer, M., Hertwig, F., Roels, F., Dreidax, D., Gartlgruber, M., Menon, R., Krämer, A., Roncaioli, J.L., Sand, F., Heuckmann, J.M., Ikram, F., Schmidt, R., Ackermann, S., Engesser, A., Kahlert, Y., Vogel, W., Altmüller, J., Nürnberg, P., Thierry-Mieg, J., Thierry-Mieg, D., Mariappan, A., Heynck, S., Mariotti, E., Henrich, K.-O., Gloeckner, C., Bosco, G., Leuschner, I., Schweiger, M.R., Savelyeva, L., Watkins, S.C., Shao, C., Bell, E., Höfer, T., Achter, V., Lang, U., Theissen, J., Volland, R., Saadati, M., Eggert, A., de Wilde, B., Berthold, F., Peng, Z., Zhao, C., Shi, L., Ortmann, M., Büttner, R., Perner, S., Hero, B., Schramm, A., Schulte, J.H., Herrmann, C., O’Sullivan, R.J., Westermann, F., Thomas, R.K., Fischer, M., 2015. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature 526, 700–704. doi.org/10.1038/nature14980

Schramm, A., Köster, J., Assenov, Y., Althoff, K., Peifer, M., Mahlow, E., Odersky, A., Beisser, D., Ernst, C., Henssen, A.G., Stephan, H., Schröder, C., Heukamp, L., Engesser, A., Kahlert, Y., Theissen, J., Hero, B., Roels, F., Altmüller, J., Nürnberg, P., Astrahantseff, K., Gloeckner, C., De Preter, K., Plass, C., Lee, S., Lode, H.N., Henrich, K.-O., Gartlgruber, M., Speleman, F., Schmezer, P., Westermann, F., Rahmann, S., Fischer, M., Eggert, A., Schulte, J.H., 2015. Mutational dynamics between primary and relapse neuroblastomas. Nat. Genet. 47, 872–877. doi.org/10.1038/ng.3349

 

SYSMED-NB-Projekte in den Medien: